Table 2 Demographics, clinical characteristics, and prognostic biomarkers in patients with versus without BRAF, FBXW7, NRAS, and/or XPO1 mutations (n = 499^a).

Patient/disease characteristic	BRAF, FBXW7, NRAS, and/or XPO1 mutation		P
Patient/disease characteristic	Yes % (n = 73)	No % (n = 426)	P
Aged >70 years	34	30	0.5
Male	78	71	0.2
Binet stage C^b	36	31	0.4
Randomised arm chlorambucil	52	47	0.5
Non-response to treatment	21	21	1.0
≥2 lines of treatment	73	66	0.3
Unmutated IGHV genes (>98% homology)^a	84	59	0.0002
β2 microglobulin ≥4 mg/L^a	55	47	0.3
CD38 positive (cut-off 7%)^a	78	61	0.02
Zap-70 positive (cut-off 10%)^a	65	47	0.02
Trisomy 12^a	29	14	0.003
11q deletion^a	24	20	0.5
Absence of 13q deletion^a	62	37	0.0001
17p deletion^a	8	5	0.5
ATM mutation	8	7	0.8
BIRC3 mutation	12	6	0.07
EGR2 mutation	1	3	0.5
KRAS mutation	15	4	0.0003
NOTCH1 mutation	21	11	0.02
SF3B1 mutation	15	26	0.05
TP53 mutation	15	9	0.09

^aEight variables had missing data, with the no. of cases ranging from 356 to 464.
^bBinet stage C disease was not significant because, while patients with these gene mutations were more likely than others to have anaemia (haemoglobin < 100 g/L; 33% versus 18%; P = 0.003), they were less likely to have thrombocytopenia (platelets < 100 × 10⁹/L; 10% versus 21%; P = 0.02).

Quick links

Search